Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer

被引：2

作者：

Yamamoto, Shinya ^{[1
,2
]}

Chishima, Takashi ^{[1
]}

Shibata, Yukako ^{[1
]}

Inoue, Shiori ^{[1
]}

Harada, Fumi ^{[1
]}

Takeuchi, Hideki ^{[1
]}

Yamada, Akimitsu ^{[3
]}

Narui, Kazutaka ^{[2
]}

Endo, Itaru ^{[3
]}

机构：

[1] Yokohama Rosai Hosp, Dept Breast Surg, Yokohama, Kanagawa, Japan

[2] Yokohama City Univ, Dept Breast & Thyroid Surg, Med Ctr, Yokohama, Kanagawa, Japan

[3] Yokohama City Univ, Dept Gastroenterol Surg, Grad Sch Med, Yokohama, Kanagawa, Japan

来源：

IN VIVO | 2022年 / 36卷 / 02期

关键词：

Breast cancer; biological features; neoadjuvant chemotherapy; prognostic factors; DISEASE-SPECIFIC SURVIVAL; DX RECURRENCE SCORE; STAGING SYSTEM; VALIDATION; EXPRESSION; WOMEN;

D O I：

10.21873/invivo.12774

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Background/Aim: There are few models predicting breast cancer prognosis among patients receiving neoadjuvant chemotherapy (NAC) for estrogen receptor (ER)-positive/ human epidermal growth factor receptor 2 (HER2)-negative (luminal) breast cancer. We examined whether biological features (BFs) of residual tumors are prognostic factors following NAC. Patients and Methods: We enrolled patients with remnant tumors following NAC for luminal breast cancer and evaluated clinical stage, pathological stage, BFs prior to NAC, and BFs following NAC as prognostic factors. BFs were divided into high and low risk using the previously reported YR-IHC4 model calculated according to ER, progesterone receptor (PgR), HER2, and the proliferation marker Ki-67. Results: A total of 57 patients were enrolled in the current study. We observed a statistically significant difference in relapse-free survival (RFS) between the BF risk categories via YR-IHC4 predictions following NAC (p=0.044). The 5-year RFS rates of the BF low- and high-risk groups following NAC were 84.2% and 52.5%, respectively. Conclusion: BFs of residual tumors following NAC may be important prognostic factors in luminal breast cancer.

引用

页码：859 / 864

页数：6

共 24 条

[1] Validation of the CPS plus EG Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy [J].

Abdelsattar, Jad M. ;

Al-Hilli, Zahraa ;

Hoskin, Tanya L. ;

Heins, Courtney N. ;

Boughey, Judy C. .

ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (10) :3206-3211

[2]

[Anonymous], 2018, ARCH PATHOL LAB MED, DOI DOI 10.5858/arpa.2018-0902-SA

[3]

Bierley JD., 2017, UICC TNM Classification of Malignant Tumours. Digestive System Tumours, V8th

[4] A risk score to predict disease-free survival in patients not achieving a pathological complete remission after preoperative chemotherapy for breast cancer [J].

Colleoni, M. ;

Bagnardi, V. ;

Rotmensz, N. ;

Dellapasqua, S. ;

Viale, G. ;

Pruneri, G. ;

Veronesi, P. ;

Torrisi, R. ;

Luini, A. ;

Intra, M. ;

Galimberti, V. ;

Montagna, E. ;

Goldhirsch, A. .

ANNALS OF ONCOLOGY, 2009, 20 (07) :1178-1184

[5] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[6] Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer [J].

Cuzick, Jack ;

Dowsett, Mitch ;

Pineda, Silvia ;

Wale, Christopher ;

Salter, Janine ;

Quinn, Emma ;

Zabaglo, Lila ;

Mallon, Elizabeth ;

Green, Andrew R. ;

Ellis, Ian O. ;

Howell, Anthony ;

Buzdar, Aman U. ;

Forbes, John F. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4273-4278

[7] Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer [J].

Fujii, T. ;

Kogawa, T. ;

Dong, W. ;

Sahin, A. A. ;

Moulder, S. ;

Litton, J. K. ;

Tripathy, D. ;

Iwamoto, T. ;

Hunt, K. K. ;

Pusztai, L. ;

Lim, B. ;

Shen, Y. ;

Ueno, N. T. .

ANNALS OF ONCOLOGY, 2017, 28 (10) :2420-2428

[8] Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy [J].

Haque, Waqar ;

Verma, Vivek ;

Hatch, Sandra ;

Klimberg, V. Suzanne ;

Butler, E. Brian ;

Teh, Bin S. .

BREAST CANCER RESEARCH AND TREATMENT, 2018, 170 (03) :559-567

[9] Neo-Bioscore in Guiding Post-surgical Therapy in Patients With Triple-negative Breast Cancer Who Received Neoadjuvant Chemotherapy [J].

Hasegawa, Yoriko ;

Matsubara, Nobuaki ;

Kogawa, Takahiro ;

Naito, Yoichi ;

Harano, Kenichi ;

Hosono, Ako ;

Onishi, Tatsuya ;

Hojo, Takashi ;

Shimokawa, Mototsugu ;

Mukohara, Toru .

IN VIVO, 2021, 35 (02) :1041-1049

[10] Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis [J].

Klein, Molly E. ;

Dabbs, David J. ;

Shuai, Yongli ;

Brufsky, Adam M. ;

Jankowitz, Rachel ;

Puhalla, Shannon L. ;

Bhargava, Rohit .

MODERN PATHOLOGY, 2013, 26 (05) :658-664

← 1 2 3 →